Skip to content
10-K/A

Annual Report

Eledon Pharmaceuticals, Inc. ELDN

0001193125-25-180865

← back to feed
Filed
Aug 14, 2025 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Aug 13, 2025 59.88M sh
Operating Cash Flow FY 2024 · Dec 31, 2024 −$47.27M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$39.53M
Short Term Investments FY 2024 · Dec 31, 2024 $119.63M
Short Term Investments FY 2024 · Dec 31, 2023 $46.49M
Cash And Equivalents FY 2024 · Dec 31, 2024 $20.55M
Cash And Equivalents FY 2024 · Dec 31, 2023 $4.61M
Stockholders Equity restated FY 2024 · Dec 31, 2024 $62.45M
Stockholders Equity FY 2024 · Sep 30, 2024 $20.36M
Stockholders Equity FY 2024 · Jun 30, 2024 −$64.2M
Stockholders Equity FY 2024 · Mar 31, 2024 −$70.42M
Stockholders Equity restated FY 2024 · Dec 31, 2023 −$48.49M
Stockholders Equity restated FY 2024 · Dec 31, 2022 $23.79M
Current Liabilities FY 2024 · Dec 31, 2024 $11.58M
Current Liabilities FY 2024 · Dec 31, 2023 $3.9M
Total Liabilities FY 2024 · Dec 31, 2024 $59.27M
Total Liabilities restated FY 2024 · Dec 31, 2023 $81.86M
Current Assets FY 2024 · Dec 31, 2024 $143.73M
Current Assets FY 2024 · Dec 31, 2023 $56.13M
Total Assets FY 2024 · Dec 31, 2024 $177.41M
Total Assets FY 2024 · Dec 31, 2023 $89.07M
Sga Expense FY 2024 · Dec 31, 2024 $18.61M
Sga Expense FY 2024 · Dec 31, 2023 $12.69M
Rd Expense FY 2024 · Dec 31, 2024 $51.96M
Rd Expense FY 2024 · Dec 31, 2023 $30.31M
Net Income FY 2024 · Dec 31, 2024 −$36.18M
Net Income restated FY 2024 · Dec 31, 2023 −$116.54M